These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8097164)

  • 1. Dynorphin A-(1-13) potently prevents memory dysfunctions induced by transient cerebral ischemia in mice.
    Itoh J; Ukai M; Kameyama T
    Eur J Pharmacol; 1993 Mar; 234(1):9-15. PubMed ID: 8097164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. U-50,488H, a kappa-opioid receptor agonist, markedly prevents memory dysfunctions induced by transient cerebral ischemia in mice.
    Itoh J; Ukai M; Kameyama T
    Brain Res; 1993 Aug; 619(1-2):223-8. PubMed ID: 8397052
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynorphin A-(1-13) potently improves the impairment of spontaneous alternation performance induced by the mu-selective opioid receptor agonist DAMGO in mice.
    Itoh J; Ukai M; Kameyama T
    J Pharmacol Exp Ther; 1994 Apr; 269(1):15-21. PubMed ID: 7909556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the kappa-opioid dynorphin A(1-13) on learning and memory in mice.
    Ukai M; Itoh J; Kobayashi T; Shinkai N; Kameyama T
    Behav Brain Res; 1997 Feb; 83(1-2):169-72. PubMed ID: 9062678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynorphin A-(1-13) potently improves galanin-induced impairment of memory processes in mice.
    Kameyama T; Ukai M; Miura M
    Neuropharmacology; 1994 Oct; 33(10):1167-9. PubMed ID: 7532287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Des-tyrosine(1) dynorphin A-(2-13) improves carbon monoxide-induced impairment of learning and memory in mice.
    Hiramatsu M; Inoue K
    Brain Res; 2000 Mar; 859(2):303-10. PubMed ID: 10719078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynorphin A-(1-13) markedly improves scopolamine-induced impairment of spontaneous alternation performance in mice.
    Itoh J; Ukai M; Kameyama T
    Eur J Pharmacol; 1993 Jun; 236(3):341-5. PubMed ID: 8102969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of dynorphin A-(1-13) on carbon monoxide-induced delayed amnesia in mice studied in a step-down type passive avoidance task.
    Hiramatsu M; Sasaki M; Kameyama T
    Eur J Pharmacol; 1995 Aug; 282(1-3):185-91. PubMed ID: 7498274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynorphin A-(1-13) potently improves scopolamine-induced impairment of passive avoidance response in mice.
    Ukai M; Kobayashi T; Shinkai N; Shan-Wu X; Kameyama T
    Eur J Pharmacol; 1995 Feb; 274(1-3):89-93. PubMed ID: 7768285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversion of muscarinic autoreceptor agonist-induced acetylcholine decrease and learning impairment by dynorphin A (1-13), an endogenous kappa-opioid receptor agonist.
    Hiramatsu M; Murasawa H; Mori H; Kameyama T
    Br J Pharmacol; 1998 Mar; 123(5):920-6. PubMed ID: 9535021
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynorphin A-(1-13) and (2-13) improve beta-amyloid peptide-induced amnesia in mice.
    Hiramatsu M; Inoue K; Kameyama T
    Neuroreport; 2000 Feb; 11(3):431-5. PubMed ID: 10718289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. kappa-Opioid receptor agonists improve pirenzepine-induced disturbance of spontaneous alternation performance in the mouse.
    Ukai M; Shinkai N; Kameyama T
    Eur J Pharmacol; 1995 Aug; 281(2):173-8. PubMed ID: 7589204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of dynorphin A (1-13) on carbon monoxide-induced delayed amnesia in mice.
    Hiramatsu M; Sasaki M; Nabeshima T; Kameyama T
    Pharmacol Biochem Behav; 1997 Jan; 56(1):73-9. PubMed ID: 8981612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic administration of dynorphin A-(1-13) markedly improves cycloheximide-induced amnesia in mice.
    Ukai M; Shan-Wu X; Kobayashi T; Kameyama T
    Eur J Pharmacol; 1996 Oct; 313(1-2):11-5. PubMed ID: 8905323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopaminergic involvement in the improving effects of dynorphin A-(1-13) on scopolamine-induced impairment of alternation performance.
    Itoh J; Ukai M; Kameyama T
    Eur J Pharmacol; 1993 Sep; 241(1):99-104. PubMed ID: 7901037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement by dynorphin A (1-13) of galanin-induced impairment of memory accompanied by blockade of reductions in acetylcholine release in rats.
    Hiramatsu M; Mori H; Murasawa H; Kameyama T
    Br J Pharmacol; 1996 May; 118(2):255-60. PubMed ID: 8735624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynorphin A-(1-13) attenuates basal forebrain-lesion-induced amnesia in rats.
    Ukai M; Kobayashi T; Kameyama T
    Brain Res; 1993 Oct; 625(2):355-6. PubMed ID: 7903901
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of U-50,488H on scopolamine-, mecamylamine- and dizocilpine-induced learning and memory impairment in rats.
    Hiramatsu M; Murasawa H; Nabeshima T; Kameyama T
    J Pharmacol Exp Ther; 1998 Mar; 284(3):858-67. PubMed ID: 9495843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of galanin on passive avoidance response, elevated plus-maze learning, and spontaneous alternation performance in mice.
    Ukai M; Miura M; Kameyama T
    Peptides; 1995; 16(7):1283-6. PubMed ID: 8545252
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Big dynorphin, a prodynorphin-derived peptide produces NMDA receptor-mediated effects on memory, anxiolytic-like and locomotor behavior in mice.
    Kuzmin A; Madjid N; Terenius L; Ogren SO; Bakalkin G
    Neuropsychopharmacology; 2006 Sep; 31(9):1928-37. PubMed ID: 16292317
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.